Lv6
2430 积分 2020-09-22 加入
Emerging Targeted Therapies for HER2-mutant Non-Small Cell Lung Cancer
4天前
已完结
Molecular Profiling across 80,000 Patients with Lung Cancer
14天前
已完结
AYVM to AYMM Transition on HER2 Exon 20 Insertion Induces Tyrosine Kinase Inhibitor Resistance in NSCLC
14天前
已完结
Acquired resistance of cancer therapies: Mechanisms and perspectives
14天前
已关闭
Efficacy of Neratinib-Based Therapy in ERBB2-Mutant Lung Adenocarcinomas: Findings From 2 International Phase 2 Studies
14天前
已完结
Therapeutic dominance of tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)
14天前
已完结
Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer
14天前
已完结
Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies
14天前
已关闭
Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives
14天前
已完结
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
14天前
已完结
皖公网安备34019202002308
